
Glass fragments found in bread: FDA recalls products in 6 US states over alarming health risks
FDA
has recalled loaves and rolls sold across six US states, after glass fragments were found in the bread. The federal agency classified the risk as Class I and warned that ingesting glass fragments can 'cause injury to the consumer including damage to teeth, laceration of the mouth and throat, or perforation of the intestine.
The recall was issued due to 'glass fragment found on top of bread" for three products that are part of Upper Crust Bakery LP - Ancient Grains Hoagie Roll, Multigrain Sourdough and Whole Grain Multigrain.
A total of 818 cases are suspected to contain glass fragments, including 699 cases of the 18-ounce sourdough loaf, which is sold frozen in corrugated paper cartons. Additionally, 89 cases of hoagie rolls and 30 cases of the whole grain multigrain loaf have been recalled.
The US states where the products were being sold include Pennsylvania, California, Connecticut, Maryland, Delaware, and Ohio. They appear to be made by Crest Hill Bakery in Maryland.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Use an AI Writing Tool That Actually Understands Your Voice
Grammarly
Install Now
Undo
Upper Crust Bakery LP said the recall was voluntary, and the company notified FDA about it on April 12. In a press release, Upper Crust Bakery LP said a vigilant team member recently discovered a small glass fragment on top of a piece of seeded bread. The glass apparently came from sunflower seeds from one of their suppliers.
"As a precautionary measure, we initiated a voluntary recall of the 3 products affected by this lot to prioritize the safety of our valued consumers," the release added.
What happens when you consume glass fragments
FDA says doing so can cause injury to the consumer. These injuries may include damage to teeth, laceration of the mouth and throat, or perforation of the intestine.
"In response, Crest Hill Bakery has worked closely with JJ Nuts and the FDA to promptly address the issue. We have ceased the use of sunflower seeds from the manufacturer associated with the glass fragments, Magic Flame," read the press release further.
"All affected products were swiftly removed from store shelves, all affected lots through the supply chain were destroyed and accounted for with no injuries associated," it added. "We are extremely confident that our swift and decisive actions, along with our exceptional Quality Systems and dedicated staff, have effectively resolved the issue. We remain steadfast in our commitment to upholding the highest standards of quality and safety in all our products."
Anyone who purchased them is advised by FDA to not eat them, discard them in a secure trash can or return them to where they were purchased and get a full refund.
COVID-era grads skip college over debt risks, jobs
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
3 hours ago
- Business Standard
Anti-rabies vaccine, immunoglobulin sales pick up as dog bite cases jump
Sanket Koul New Delhi Listen to This Article Anti-rabies vaccine (ARV) and immunoglobulin sales are gradually recovering after the Covid-19 slump, amid a marked increase in dog bite incidence. The rise in sales follows a 76 per cent increase in dog bites, from 2.1 million in 2022 to 3.7 million in 2024. As a result, vaccine makers are preparing to ratchet up production. Bharat Serums and Vaccines (BSV), an arm of Mankind Pharma, told Business Standard that it aims to expand manufacturing by 15-20 per cent, supporting India's mission to eliminate rabies through timely and complete after-exposure treatment. Data from market research firm Pharmarack shows that the combined
&w=3840&q=100)

Business Standard
7 hours ago
- Business Standard
PM Modi asks scientists to focus on R&D, secure patents for new drugs
Prime Minister Narendra Modi on Friday asked scientists and entrepreneurs to focus more on research and development (R&D) and secure patents for new drugs and medical technologies to ensure self-reliance in the pharmaceutical segment. Speaking from the Red Fort on the occasion of India's 79th Independence Day, PM Modi said that this move will ensure that India not only meets its own healthcare needs but also becomes a global hub of medical innovation. The call comes at a time when India has been lagging behind in terms of R&D spending, according to a Department of Pharmaceuticals (DoP) study paper on industry-academia linkages in the segment. It states that while a number of initiatives for industry-academic linkages in India have produced positive research results over the years, due to their sporadic nature, India's share of world researchers has remained at about 2 per cent, compared to 20 per cent in the US and China. 'An analysis of the share in R&D reveals that in India, the government contributes between 75 and 80 per cent, the private sector contributes 20 to 25 per cent, and universities contribute 3 per cent,' the paper added. In comparison, OECD countries see a 69 per cent contribution from private sector companies, followed by universities at 18 per cent, government contribution at 10 per cent, and non-profit organisations at 3 per cent. Commenting on the issues faced by the pharma industry, Kiran Mazumdar-Shaw, executive chairperson of Biocon and Biocon Biologics, told CNBC TV18 that the timeline to take a new molecule from the lab to the market is a very long process, making investments in research and innovation very risky. 'Unless we have very bold regulatory reforms that shorten this lab-to-market journey, we may not see the research investment needed for a country like India,' she added. Calling on the industry to demonstrate India's ability to lead in science, technology, and human welfare, PM Modi also urged the nation to achieve self-reliance in medicines and innovation, highlighting the country's strength as the pharmacy of the world. India currently has approximately 3,000 pharmaceutical businesses with over 10,500 manufacturing facilities, offering around 60,000 generic brands in 60 therapeutic categories. Many Indian pharmaceutical companies are now looking to jump on the generic bandwagon for off-patent molecules, while pressing on plans to develop a biosimilars pipeline post the Covid-19 pandemic. Pharma firms have gone on a generic spree after several blockbuster molecules used in diabetes medications, such as empagliflozin and dapagliflozin, went off patent in the last two years. Major blockbuster molecules that have seen several generic launches in this timeframe include empagliflozin and dapagliflozin, used in diabetes medications, which saw the prices of these drugs fall by 85 per cent in the Indian market. Similarly, companies such as Sun Pharma, Torrent, Lupin, Glenmark, and Dr Reddy's are also working on generic versions of weight loss drugs based on the blockbuster molecule semaglutide, which is expected to go off patent by March 2026. According to the DoP's study paper, more than 300 drug patents in different categories and geographies will be expiring every year during the patent cliff period of 2022 to 2032. 'The patent cliff will provide an opportunity for Indian generic companies to enter the US and other regulated markets and produce more affordable versions of those medications,' the paper added. PM flags obesity crisis in I-Day speech, calls for less oil intake PM Modi on Friday expressed concerns over obesity becoming a future crisis for India, asking people to cut down consumption of cooking oil by at least 10 per cent. India is currently projected to have the third-highest population of overweight or obese people globally, after the United States of America (USA) and China. Asking every family to take the concern seriously, the Prime Minister resolved that the country must protect itself from obesity. 'While many steps will have to be taken, I have made one small suggestion that every family should resolve that when cooking oil comes into the house, it should be 10 per cent less than usual, and its use should also be 10 per cent less. By doing so, we shall make our contribution towards winning the fight against obesity,' he stated from the ramparts of the Red Fort. According to the National Family Health Survey-5 (2019-21), 24 per cent of women and 23 per cent of men in India are overweight or obese, a sharp rise from 20.7 per cent and 18.6 per cent recorded in the NFHS-4 (2015-16), respectively. A recent Lancet study had also predicted that nearly one-third of the country's population, amounting to 218 million men and 231 million women, will be obese by 2050.
&w=3840&q=100)

Business Standard
10 hours ago
- Business Standard
PM Modi urges scientists to focus on R&D, secure patents for new drugs
Prime Minister Narendra Modi on Friday urged scientists and entrepreneurs to focus more on research and development (R&D) and secure patents for new drugs and medical technologies to ensure self-reliance in the pharmaceutical segment. Speaking from the Red Fort on the occasion of India's 79th Independence Day, Modi said this would enable the country not only to meet its own healthcare needs but also to emerge as a global hub of medical innovation. The call comes at a time when India has been lagging in R&D spending, according to a Department of Pharmaceuticals (DoP) study paper on industry–academia linkage in the segment. The paper states that while a number of initiatives for industry–academic linkages in India have produced positive research results over the years, their sporadic nature has kept India's share of world researchers at about 2 per cent, compared to 20 per cent in the United States and China. 'An analysis of the share in R&D reveals that in India, the government contributes between 75 and 80 per cent, the private sector 20 to 25 per cent, and universities 3 per cent,' the paper noted. In comparison, OECD countries see 69 per cent of R&D funding from private sector companies, followed by universities at 18 per cent, government at 10 per cent, and non-profit organisations at 3 per cent. Calling on industry to demonstrate India's ability to lead in science, technology, and human welfare, Modi also urged the nation to achieve self-reliance in medicines and innovation, highlighting the country's role as the pharmacy of the world. India currently has around 3,000 pharmaceutical businesses with over 10,500 manufacturing facilities, offering about 60,000 generic brands in 60 therapeutic categories. Many Indian pharmaceutical companies are now pursuing opportunities in generic production for off-patent molecules while building biosimilars pipelines after the Covid-19 pandemic. Pharma firms have stepped up generic launches after several blockbuster molecules used in diabetes medications, such as empagliflozin and dapagliflozin, went off patent in the past two years. Prices of these drugs have fallen by as much as 85 per cent in the Indian market. Similarly, companies such as Sun Pharma, Torrent, Lupin, Glenmark, and Dr Reddy's are working on generic versions of weight-loss drugs based on the blockbuster molecule semaglutide, which is expected to go off patent by March 2026. According to the DoP study paper, more than 300 drug patents across different categories and geographies are set to expire every year during the 'patent cliff' period from 2022 to 2032. 'The patent cliff will provide an opportunity for Indian generic companies to enter the US and other regulated markets and produce more affordable versions of those medications,' the paper added.